Role of surgical intervention in managing gastrointestinal metastases from lung cancer

Lee, Po‐Chu; Lo, Chiao; Lin, Min; Liang, Jin–Tung; Lin, Bi‐Fong

doi:10.3748/wjg.v17.i38.4314

Cited by 82 publications

(95 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the clinical incidence of gastrointestinal metastasis of lung cancer has been reported to be as low as 0.2-1.7% (3)(4)(5)(6)(7)(8). By contrast, the rate of metastasis of primary lung cancer to the gastrointestinal tract in autopsy studies is higher than the clinical frequency of gastrointestinal metastasis.…”

Section: Introductionmentioning

confidence: 67%

“…However, in past clinical studies, the incidence of gastrointestinal metastasis has been reported to be as low as 0.2-1.7% (5)(6)(7)(8), and in the current study, the clinical prevalence of gastrointestinal metastasis of lung cancer was ~0.33% (7/2,066). The method underlying the spread of metastasis to the intra-abdominal region is believed to involve hematogenous and lymphatic routes (12).…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis

Taira

Kawabata

Gabe³

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The prevalence of gastrointestinal metastasis of lung cancer is low. The aim of the present study was to analyze the frequency and clinical characteristics of metastases to the gastrointestinal tract by retrospectively assessing the clinical records of 2,066 patients with lung cancer. A total of 7 patients (0.33%) were diagnosed with gastrointestinal metastasis, including 4 patients with adenocarcinoma, 1 patient with large cell carcinoma and 2 patients with pleomorphic carcinoma. Furthermore, 3 of the patients presented with small bowel metastases, 2 with gastric metastases, 1 with large bowel metastasis and 1 with metastasis of the appendix. The mean time between the diagnosis of the lung tumors and the identification of gastrointestinal metastasis was 13.5 months (range, 3-49 months). The mean time between the identification of the gastrointestinal metastasis and mortality was 100.6 days (range, 21-145 days). In conclusion, the prognosis of patients with recurrence in distant organs, including the gastrointestinal tract, may be worse than patients with recurrence in distant organs, excluding the gastrointestinal tract, particularly those with symptomatic gastrointestinal metastasis. Therefore, the presence of clinical gastrointestinal metastasis may be life threatening; comprehensive evaluations are required to detect and monitor gastrointestinal metastasis during follow-up.

show abstract

Section: Introductionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 90%

Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis

Taira

Kawabata

Gabe³

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…1) Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all pulmonary carcinoma cases. This cancer is categorized into histological subtypes of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.…”

mentioning

confidence: 99%

The Effect of a Retinoic Acid Derivative on Cell-Growth Inhibition in a Pulmonary Carcinoma Cell Line

Akita

Horiguchi

Ozawa

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Pulmonary carcinoma is a major cause of cancer-related death worldwide. Because the prognosis remains poor, the development of novel therapeutic approaches is highly desirable. In this study, we investigated the effect of Tamibarotene (Am80), a retinoic acid derivative, on the growth of human lung adenocarcinoma cell line A549. Our ultimate goal in this study is to provide pulmonary carcinoma therapy with a new approach. First, we treated A549 cells with Am80 to clarify the effect of cell-growth inhibition. Am80 significantly reduced the viability of A549 cells in a dose-and time-dependent manner. The IC 50 value, which was determined using CellTiter-Glo Luminescent Cell Viability assay, of Am80 and all-trans retinoic acid (ATRA) against A549 cells at 6 d was 49.1 8.1 µM and 92.3 8.0 µM, respectively. Furthermore, Am80 reduced the anchorage-independent cell-growth ability of A549 cells. However, it was not an apoptosis-mediated mechanism. These results suggest that Am80 can be used as an effective, novel cell-growth inhibitor in lung adenocarcinoma.Key words Tamibarotene (Am80); cell-growth inhibition; pulmonary carcinoma; retinoid Pulmonary carcinoma is a major cause of cancer-related death worldwide.1) Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all pulmonary carcinoma cases. This cancer is categorized into histological subtypes of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.2) Because the prognosis of NSCLC remains poor, the development of novel therapeutic approaches is highly desirable.3) Lung adenocarcinoma, accounting for approximately 40% of all pulmonary carcinomas, is currently one of the most common histological types and its incidence has gradually increased in recent years in many countries. 4)Conventional chemotherapeutic regimens against most solid tumors have reached an efficacy plateau and display significant toxicity. In the last decade, the targeted inhibition of oncogenic driver mutations with molecular therapies, of which the epidermal growth factor receptor (EGFR) and the anaplastic lymphoma kinase (ALK) are the most studied targets, has brought dramatic improvements in the overall survival in defined subsets of patients.5) Unfortunately, in many cases, patients develop resistance to these agents via secondary mutations and alternative mechanisms. 6)In this study, we focused on a retinoic acid derivative as a cell-growth inhibitor in lung adenocarcinoma. Retinoids can inhibit the growth and modulate the differentiation of a variety of tumor cell types in vitro and in vivo.7) A novel synthetic retinoid, Tamibarotene (Am80), has been developed and applied as acute promyelocytic leukemia treatment. Am80 offers higher differentiation-inducing property and is approximately ten times more potent than all-trans retinoic acid (ATRA) as an in vitro inducer of differentiation in NB-4 and HL-60 leukemia cells. 8,9) In addition, Am80 is chemically more resistant to light, heat, and oxidation and has higher receptor selectivity compared with ATRA. Am80 is a...

show abstract

“…Surgical intervention in patients with lung cancer metastatic to the stomach remains controversial as some authors report longer survival rates in the best supportive care approach (37), while others support metastasectomy in patients with non-small cell lung cancer and unique metastasis not involving the brain or the adrenal gland (38,39). However, life-threatening complications such as massive hemorrhage or perforation can be prevented by surgical intervention (37,40). Therefore, treatment should be personalized.…”

Section: Discussionmentioning

confidence: 99%

A rare case of advanced lung cancer presenting as a symptomatic gastric tumor

et al. 2018

View full text Add to dashboard Cite

Abstract. Although gastric metastases have been estimated to occur in less than 2% of cancer patients, an increased use of upper digestive tract endoscopy allows for a higher detection of secondary gastric tumors. We describe the case of a 66-year-old male patient presenting with mild pain in the sternum and upper abdominal area. Physical examination revealed a right parietal skull tumor, with no other significant clinical changes. Upon exclusion of an acute coronary syndrome, upper digestive tract endoscopy was performed, showing the presence of an ulcerated tumor located in the gastric fundus. Histopathologic examination of the biopsy sample and immunohistochemical tests suggested a pulmonary origin of the gastric tumor. Whole body computer tomography showed the presence of tumors in the gastric fundus, left lung, liver, kidneys, bones and brain. Transbronchial biopsy of the lung tumor certified the diagnosis of non-small cell lung cancer, with the same immunohistochemical profile as the gastric tumor. Hence, it was considered the origin of the metastases. Biopsy of the skull tumor also had the identical tumor histology. Whole brain radiotherapy was performed for the brain metastases and subsequent chemotherapy was administered. Although non-specific, gastrointestinal signs and symptoms occurring in lung cancer patients should alert the clinicians as to the possibility of gastrointestinal metastases and prompt endoscopic evaluation.

show abstract

Role of surgical intervention in managing gastrointestinal metastases from lung cancer

Abstract: Patients with acute pancreatitis are liable to suffer from PUD. PUD is associated with severe acute pancreatitis according to the APACHE II score, and treatment for PUD should be considered for patients with severe acute pancreatitis.

Cited by 82 publications

References 25 publications

Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis

Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis

The Effect of a Retinoic Acid Derivative on Cell-Growth Inhibition in a Pulmonary Carcinoma Cell Line

A rare case of advanced lung cancer presenting as a symptomatic gastric tumor

Contact Info

Product

Resources

About